



TITLE:

Clinical and immunological characterization of paraneoplastic retinopathy.

AUTHOR(S):

Makiyama, Yukiko; Kikuchi, Takanobu; Otani, Atsushi; Oishi, Akio; Guo, Congrong; Nakagawa, Satoko; Ogino, Ken; Kojima, Hiroshi; Kurimoto, Masafumi; Yoshimura, Nagahisa

CITATION:

Makiyama, Yukiko ...[et al]. Clinical and immunological characterization of paraneoplastic retinopathy.. Investigative ophthalmology & visual science 2013, 54(8): 5424-5431

ISSUE DATE:

2013-08

URL:

<http://hdl.handle.net/2433/187393>

RIGHT:

© Association for Research in Vision and Ophthalmology; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。
。; This is not the published version. Please cite only the published version.

Clinical and Immunological Characterization of Paraneoplastic Retinopathy

Short title: Characterization of Paraneoplastic Retinopathy

Yukiko Makiyama,¹ Takanobu Kikuchi,² Atsushi Otani,¹ Akio Oishi,¹ Congrong Guo,¹ Satoko Nakagawa,¹ Ken Ogino,¹ Hiroshi Kojima,¹ Masafumi Kurimoto,¹ Nagahisa Yoshimura,¹

¹Department of Ophthalmology, Kyoto University Graduate School of Medicine,
Kyoto 606-8507, Japan

²Department of Instrumental Analysis Research Center for Human and
Environmental Science, Shinshu University, Nagano 390-8621, Japan

All correspondence should be addressed to:

Atsushi Otani, MD, PhD

Department of Ophthalmology, Kyoto University Graduate School of Medicine

54-Kawaharacho, Shyogoin, Sakyo-ku, Kyoto 606-8507, Japan

E-mail: otan@kuhp.kyoto-u.ac.jp, Fax: +81-75-752-0933

Tel: +81-75-751-3248

Key words: paraneoplastic retinopathy, spectral domain-optical coherence tomography, Western blot analysis, immunohistochemistry, autoantibody, anti-retinal antibody

Abstract

Purpose: To report the clinical and immunological characterization of paraneoplastic retinopathy and to investigate the association between spectral domain-optical coherence tomography (SD-OCT) findings and the target of autoantibodies in paraneoplastic retinopathy (PR).

Design: Observational case series.

Methods: We retrospectively enrolled 8 patients (age, 57–85 years; 4 men and 4 women) suspected to have PR. All patients underwent comprehensive ophthalmic examinations, including best-corrected visual acuity (BCVA) measurement, slit-lamp examinations, kinetic visual field testing with Goldmann perimetry (GP), electroretinography (ERG), fundus photography, fluorescein angiography (FA), fundus autofluorescence (FAF), SD-OCT, and experimental serum examinations (Western blot analysis and immunohistochemistry [IHC]).

Results: Three patients had previous history of malignant tumors, and 4 were newly diagnosed with neoplastic tumors (small cell lung carcinoma, thymoma, pancreatic neuroendocrine neoplasm, and colon cancer). Another *de novo* malignancy (small cell lung carcinoma) was detected in 1 patient with a previous history of malignancy (bladder cancer and liposarcoma). BCVA in these patients ranged from hand motion to 1.5. The GP revealed island, ring-shaped, concentric, or central scotoma. All the patients showed non-recordable or reduced amplitude ERG. Fluorescein leakage was detected in 5 patients. Hyper- and/or hypo- autofluorescence on FAF was detected in 6 cases. The serum examinations identified anti-retinal antibodies in all of the patients. Patients whose serum contained anti-photoreceptor or anti-RPE antibody as evidenced with IHC showed damages of outer retina in OCT.

Conclusions: In this case series, PR was associated with a variety of neoplasms and autoantibodies. SD-OCT can be used to characterize morphologic changes and the changes were associated with the target of autoantibodies.

Introduction

Autoimmune retinopathy (AIR) is a progressive retinal degeneration caused by autoimmune processes. These processes are considered to be mediated by autoantibodies directed to retinal proteins. AIR cases with underlying malignant or benign tumors are termed paraneoplastic retinopathies (PRs). This classification includes cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR),¹ and lymphoma-associated retinopathy (LAR).² One mechanism for PR development is hypothesized as the production of autoantibodies against common proteins expressed in both the neoplasm and the retina.^{3, 4}

PR was first described in 1976 by Sawyer et al.⁵ Subsequent case reports classified characteristic clinical features including a sudden and progressive loss of vision associated with photopsia, ring scotoma or concentric visual field defects, attenuated retinal arterioles, and abnormal electroretinograms (ERG).¹ The presence of circulating serum autoantibodies specific to retinal antigens is necessary for a diagnosis of PR; however, this laboratory test is not available in most ophthalmological settings.⁶ Western blot can be used to detect anti-retinal antibodies.⁷ However, the lack of standardization across studies makes it difficult to compare the results obtained by various authors.⁸⁻¹⁰

Recent progress in imaging technology has allowed us to detect detailed retinal changes and provided insight into the pathological mechanisms underlying retinal diseases. Optical coherence tomography (OCT), which allows for the noninvasive visualization of normal retina as well as of pathologic conditions, is now widely accepted as a standard tool in clinical practice.¹¹ The currently available spectral domain-OCT (SD-OCT) machines achieve resolution up to 5 μm ; indeed, recent SD-OCT devices allow for “layer by layer” evaluation of the retina.^{12, 13} Previous reports showed that various imaging modalities can be used to strengthen a diagnosis of CAR or PR.^{14, 15} However, there is limited information about the SD-OCT findings associated with PRs. One of the purposes of this study is to find any clinical characteristic features including SD-OCT findings seen in patients with PR. We also investigated the association with clinical characteristics and serum testing (e.g., Western blot analysis and immunohistochemistry [IHC]) to confirm the diagnosis and to understand the molecular basis of the pathologic changes.

Methods

Subjects and clinical examinations

The study comprised of 8 patients (4 men and 4 women) who were seen at Kyoto University Hospital (Kyoto, Japan) from June 2008 to August 2011 and who were suspected to have PR. The study was conducted in accordance with the tenets of the Declaration of Helsinki. The study design was approved by the Ethics committee of Kyoto University. Two of the 8 patients were presented in a prior case report without describing Western blot data and OCT findings.¹⁶

PR was suspected when a patient showed rapidly progressing vision loss and/or a visual acuity defect, which cannot be explained by fundus examination findings or the pathophysiology of other retinal or optic nerve diseases. The attenuation of retinal arterioles or the presence of photophobia was considered to support a diagnosis of PR. In such cases, we performed Goldmann perimetry (GP), ERG, fluorescein angiography (FA), fundus autofluorescence imaging (FAF), and SD-OCT. Systemic screening was accomplished using computed tomography (CT). Additional examinations with endoscopy or bronchoscopy were performed as needed. Informed consent was obtained from the participants after the objectives and the nature of the procedures had been explained fully; blood samples were collected thereafter. We diagnosed patients as having PR when they showed: (1) reduced amplitude of ERG; (2) presence of anti-retinal autoantibodies; (3) previous or newly detected neoplasm; (4) acute or subacute disease progression.

Retinal section images were acquired using a Spectralis HRA+OCT[®] (Heidelberg Engineering, Heidelberg, Germany). Built-in Automatic Real Time (ART) software was used to average images in order to improve the signal to noise ratio. We obtained 9-mm cross sections setting the ART function to 100 frames per scan. We also acquired 9-mm radial sections centered on the fovea, for which 20 images were averaged. FAF and FA images were obtained using confocal angiography (HRA2; Heidelberg Engineering). Full-field ERGs were recorded using LS-C (Mayo Co, Nagoya, Japan) and Neuropack MEB-2204 (Nihon Kohden, Tokyo, Japan) software according to the ISCEV standard protocol recommended in 2008.¹⁷

Western Blot Analysis

Serum was obtained from each patient and analyzed by Western blot as previously reported.¹⁸ Briefly, retina, brain, kidney, liver, and spleen tissue

samples from C57BL/6 mice were homogenized. Extracted proteins were used to detect organ-specific antibodies. Proteins from each organ were separated by 8% or 10% SDS-PAGE electrophoresis and transferred to polyvinylidene difluoride (PVDF) membranes. The membrane was probed with the patient's serum, then rinsed and incubated with alkaline phosphatase-conjugated goat anti-human IgG (Jackson Immuno Research, West Grove, PA). The associated signal was detected with a BCIP (5-bromo-4-chloro-3'-indolylphosphatase *p*-toluidine salt) /NBT (nitro-blue tetrazolium chloride) (BCIP/NBT) detection system. When bands were observed in retina and/or brain lanes but not in the other lanes, the serum was judged as having anti-retina specific antibodies. In addition, the presence of anti-recoverin antibody was investigated using a commercial product provided by Athena Diagnostics (Worcester, MA).

Immunohistochemistry (IHC)

C57BL/6 mouse eyes were fixed by immersion at 4°C for 12 h in a freshly prepared solution of 0.5% zinc chloride, 17.16 mM zinc trifluoroacetate, and 0.05% calcium acetate in 0.1 M Tris-HCl pH 6.5, then embedded in paraffin. Four- μ m-thick sections were prepared, deparaffinized, and blocked with 4% normal goat serum, 0.1% Triton X-100, and 0.05% NP-40 in PBS for 1 h at room temperature. The slides were then incubated with a 1:50 dilution of the patient's serum overnight at 4°C. Next, the specimens were rinsed in PBS and incubated with the Alexa Fluor 488-conjugated anti-human IgG antibody (Invitrogen, Carlsbad, CA). In some cases, the retinal slices were co-incubated with rhodamine-conjugated peanut agglutinin (Sigma-Aldrich, St. Louis, MO), rabbit polyclonal antibodies against blue opsin (Chemicon, Temecula, CA) or S-100 protein (Dako, Glostrup, Denmark). These antibodies were used to label the outer segments of cone cells, the outer segments of s-cone cells and Müller cells, respectively. In these cases, Alexa Fluor 594-conjugated anti-rabbit IgG was used as a secondary antibody. The slides were finally mounted in a mounting medium containing diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA). The contribution of secondary antibodies to the observed immune reaction was verified by staining without the primary antibody. The sections were examined using a confocal scanning microscope (LSM 5 Exciter, Carl Zeiss Microimaging, Jena, Germany).

Genetic analysis

Genomic DNAs were prepared from peripheral blood using a DNA extraction kit (QuickGene-610L; Fujifilm, Minato, Tokyo, Japan) according to the manufacturer's protocol, and the A260/A280 optical density was evaluated. The DNA from each patient except that of case 3 was submitted to genetic analysis to exclude the presence of genes linked to retinal degeneration: *CERKL*, *CNGA1*, *CNGB1*, *MERTK*, *PED6A*, *PED6B*, *PNR*, *RDH12*, *RGR*, *RLBP1*, *SAG*, *TULP1*, *CRB*, *RPE65*, *USH2A*, *USH3A*, *LRAT*, *PROML1*, and *PBP3*. The tests were performed with using a microarray (Asper Ophthalmics, Tartu, Estonia).

Results

Clinical findings

The clinical findings are summarized in Table. Initial BCVA ranged from hand motion to 1.5. All patients complained of reduced visual acuity or visual field defects. GP showed island, ring-shaped, concentric, or central scotoma.

The ERG results are shown in Figure 1. ERG revealed abnormalities in all cases, but the degree of impairment ranged from non-recordable to slight changes in the cone response in one eye.

Vasculitis as confirmed by fluorescein leakage from the vasculature was observed in 5 cases (cases 2, 3, 4, 5, and 7). Two patients (cases 3 and 4) also had vitreous opacities. FA revealed a petaloid leakage in case 4.

Three patients had previous history of malignant tumors (Bladder cancer, liposarcoma, thymoma, renal cancer, lymphoma, and renal cancer), and 4 were newly diagnosed with neoplastic tumors (small cell lung carcinoma, thymoma, pancreatic neuroendocrine neoplasm, and colon cancer). Another *de novo* malignancy (small cell lung carcinoma) was detected in 1 patient with a previous history of malignancy (bladder cancer and liposarcoma).

Fundus autofluorescence findings

In most cases, abnormality of FAF was detected. Abnormal hyper- and/or hypo-autofluorescence was noted at presentation except for case 5 and 8 (Figure 2). Although cases 5 and 8 displayed no detectable abnormality at initial examination, case 8 developed abnormal hyper- and hypo- autofluorescent lesions in 3 years. Eventually, abnormal FAF was confirmed in 7 patients of 8 patients (87.5%).

OCT findings

OCT images revealed evidence of retinal degeneration in all cases, especially in outer retina (Figure 2, right). The detected changes include the obscuration, the interruption, or the disappearance of the inner and outer segments junction of the photoreceptors (IS/OS). External limiting membrane (ELM) was also affected in case 1, 2, 3, 4, 5, 7, and 8. Thinning of foveal or parafoveal outer nuclear layer was noted in case 2, 3, 4, 6, 7, and 8. Case 4 showed cystoid macular edema.

Western blot

The results of Western blot are shown in Figure 3 and Table. Western blot analysis detected anti-retinal antibodies in all sera samples. Several bands specific to retinal proteins were observed. Anti-recoverin antibody was present in case 2. The molecular weights and the number of bands detected varied among patients.

Comparison between Immunohistochemistry and SD-OCT

High-magnification IHC and OCT images are shown in Figure 4. Abnormalities of outer retina were more easily confirmed in magnified SD-OCT images (Figure 4, upper panels). Patients' serum reacted to retinal tissue as shown in the lower panels of Figure 4.

In cases 2, 3, 4, and 5, SD-OCT showed disruption of outer retinal structures (Figure 4-2, 3, 4, and 5). IHC staining was detected in inner or outer segment in these cases (Figure 4-B, C, D, and E). In cases 7 and 8, IHC staining was detected in RPE layer (Figure 4-G, H) and OCT showed the obscuration of IS/OS line (Figure 4-7, 8). Case 1, which showed strong staining in the inner retinal layers on IHC had relatively preserved outer retina on SD-OCT image (Figure 4-1, A). In case 6, IHC staining was most prominent in the ganglion cell layer (Figure 4-F). SD-OCT image showed the thinning of outer nuclear layer, interruption of IS/OS (Figure 4-6). In addition, thinning of retinal nerve fiber layer was noted in this case (Figure 2-R).

Genetic analysis

To rule out genetic retinal degenerations, mutation screening was carried out by using microarray of Asper Ophthalmics. Candidate gene mutations included *CERKL*, *CNGA1*, *CNGB1*, *MERTK*, *PED6A*, *PED6B*, *PNR*, *RDH12*, *RGR*, *RLBP1*, *SAG*, *TULP1*, *CRB*, *RPE65*, *USH2A*, *USH3A*, *LRAT*, *PROML1*, and *PBP3*. No mutations were detected on these 7 patients by the analysis. Mutation

screening was not performed in case 3 because informed consent about genetic analysis was not obtained.

Discussion

In the present study, we reported 8 patients with PR induced by various tumors. The underlying neoplasms that induced PR were bladder cancer, liposarcoma, thymoma, lymphoma, and renal cancer. In 5 patients, diagnoses of SCLC, thymoma, pancreatic neuroendocrine neoplasm, and colon cancer were made after patients presented with retinopathy. Although SCLC is the most common cause of PR,^{1, 4, 5, 6, 16,19-21} other systemic neoplasms including bladder cancer, thymoma, liposarcoma, and renal cancer have also been associated with PR.^{4, 22} Neuroendocrine carcinoma of the fallopian tube has also been reported as a cause of PR.²³ To our best knowledge, pancreatic neuroendocrine neoplasm has not been reported as a cause of PR.

In PR, autoantibodies against retinal antigens are considered to cause retinal dysfunction and retinal cell death. Anti-recoverin antibody, which recognizes a 23 kDa retinal protein found in rod and cone photoreceptors as well as tumor cells, is the most studied autoantibody.^{20-22, 24-27} Anti-recoverin autoantibodies bind to photoreceptor cells and triggers apoptosis.^{21, 28, 29} In the present study, anti-recoverin antibody was detected in only one patient (Case 2) and the other patients showed unidentified antibodies. The protein targets of autoantibodies reported to cause PR to date include retinal alpha-enolase (46 kDa);³⁰⁻³² arrestin (48 kDa);^{33, 34} Tubby-like protein 1 (TULP1) (78 kDa);³⁵ heat shock cognate protein (hsc) 70 (65 kDa);^{36, 37} transducin beta (35 kDa);³⁸ anti-carbonic anhydrase II (30 kDa); photoreceptor cell-specific nuclear receptor(46.5 kDa);³⁹ interphotoreceptor retinoid binding protein (145 kDa);⁴⁰ TRPM1 (~180 kDa or ~200 kDa)^{41, 42}. A number of retinal antigen that were not identified have been described by western blot analysis.^{7, 8, 43} In the present study, anti-recoverin antibody was detected in only one patients and western blot detected a various bands. We were not able to determine antigens for various molecular weight proteins. However, for example, in case1, a band of molecular weight 36 kDa was detected in Western blot, which was close to molecular weights of 35 kDa reported by Peek et al as antigen against Müller cells⁴⁴ and in fact, Müller cells were stained in this case. In case 5, Western blot detected a band of molecular weight 46 kDa. Although the protein was not identified, anti-alpha-enolase antibodies (46 kDa) were reported as a cause of

cone dysfunction.³² Central visual field defect and almost non-recordable cone ERG in this patient is consistent with the report. Although it is not clear that all the detected bands have pathologic significance, the existence of these various autoantibodies, suggests that the pathology, symptoms, and clinical signs of PR are multi-faceted.

In the present study, SD-OCT images were compared to the results of IHC or Western blot. The patients with presumed anti-photoreceptor antibodies (cases 2, 3, 4, and 5) and anti-RPE antibodies (cases 7 and 8) exhibited severe damage to the outer retina and poor visual acuity. However, the patients without presumed anti-photoreceptor or anti-RPE antibodies (cases 1 and 6) exhibited relatively preserved IS/OS lines and had good visual acuity. This result is consistent with the report by Kondo et al. In their report, a patient with anti-TRPM1 antibody, which is expressed in ON bipolar cells, presented signals of INL and OPL but not photoreceptor degeneration in IHC and almost normal retinal structure in OCT images.⁴² The severe degeneration of photoreceptors depicted with SD-OCT might be associated with the presence of anti-photoreceptor or anti-RPE antibodies. Although this was an observational study and further investigations are needed, SD-OCT may facilitate the management of PR cases.¹⁵

FAF was also useful to detect the abnormality in patients with PR, as shown in previous reports.^{15, 45} In fact, abnormal FAF was noted in 7 out of 8 patients. Variety of the appearance including perivascular hyperautofluorescence and mottled hypoautofluorescence or ring-shaped hyperautofluorescence was consistent with the previous report.¹⁵ In the present study, there was one patient who showed normal FAF. A patient with normal FAF was also noted in the previous report and the authors suggested several explanations, 1: the patient was identified very early in the disease process. 2: the autoantibodies alter normal retinal function but did not cause cell loss. 3: vision loss was due to inner retinal dysfunction rather than photoreceptor disruption or loss.¹⁵ In the present study, the first explanation above was not likely because abnormality of FAF was not observed even after 12 months. The second and third explanation was not applicable either, since OCT and ERG showed outer retinal abnormality. Further studies are required to understand the relationship between retinal dysfunction, pathologic process, and FAF finding in patients with PR.

It was reported that retinopathy sometimes precedes the detection of

malignancy.⁴ In fact, neoplasms were detected after the presentation of retinopathy in 5 out of 8 patients in the present series. Thus, it is important to diagnose PR in a timely fashion. PR presented in our study shared the characteristics with previously reported cases: rapid, progressive, painless vision loss associated with photosensitivity that continued over a period ranging from weeks to months. In addition, patients with PR sometimes show asymmetric involvement in the right and left eyes, as shown in case 6. This characteristic is atypical among patients with inherited retinal degeneration. Although it is still a challenge to diagnose PR in many cases because of the variety of clinical appearances and the technical difficulty of detecting autoantibodies in serum,⁸ clinicians should be careful when faced with a case with rapid, atypical or asymmetric retinal degeneration.

In addition to the difficulty of achieving an accurate PR diagnosis and despite the common use of steroids to treat PR, no definitive therapeutic protocol has been established.⁷ The prognosis is not good in many cases. In fact, 5 of 8 patients eventually display visual acuity worse than 0.1 in both eyes. Further investigations are warranted to establish effective treatment for this disease.

Some cases with CAR were reported to show specific ERG patterns. For example, negative ERG results were reported in patients with MAR or with anti-TRPM1 (~180kDa or ~200kDa) antibody.⁴² In the current study, scotopic and photopic ERG results were equally affected in 7 cases, none of which exhibited a negative pattern. Adamus et al. reported that anti-enolase (46 kDa) antibody predominantly affected the photopic response, while anti-transducin (40 kDa) antibody predominantly affected the scotopic response, and anti-recoverin antibody reduced both responses.¹ Anti-46 kDa protein antibody was seen in cases 5 and 7, scotopic and photopic ERG results were equally affected. Although case 6 exhibited a reduced cone response in the right eye, he did not have anti-46 kDa protein antibody. We did not find any specific correlation between laboratory data and ERG findings in this series of patients.

There are several limitations in this study. The first is its retrospective design and the small number of patients. The second limitation is that we were not able to identify the anti-retinal antibody. Considering that Shimazaki et al. reported the presence of anti-retinal antibodies in normal sera,⁴⁶ all the antibodies detected in the present report might not always be the cause of the patient's PR. With regard to the anti-retinal antibody, there is another limitation;

Western blot and IHC were performed using mice retina. Although the human retina would be most suitable for the detection of autoantibodies, human sample was not available. Considering that a previous study indicates that the retina from other species can be a substitute as long as there is an appropriate control,⁸ we assume that the effect of using mice retina instead of human retina should be minimal. In fact, most previous studies used bovine, pig, monkey, rat, and mouse as well as human retina.^{7, 18, 20, 31, 35, 36, 40, 44, 47, 48} The third limitation is the clinical diagnosis of PR. Although we screened major genetic mutations and the presentation is not typical, we could not completely rule out genetic retinal degenerations in our cases.

Finally, we reported the result of clinical findings and experimental serum examinations in 8 patients with PR. Although there was a variety in morphologic changes depicted with SD-OCT as well as in targets of autoantibodies, SD-OCT and IHC findings showed some correlation. SD-OCT might be a potential tool for further investigation of the pathophysiology associated with PR.

References

1. Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. *BMC Ophthalmol* 2004;4:5.
2. Matus G, Dicato M, Focan C. [Cancer associated retinopathy (CAR). Two clinical cases and review of the literature]. *Rev Med Liege* 2007;62:166-169.
3. Adamus G. Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy. *Autoimmun Rev* 2003;2:63-68.
4. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. *Autoimmun Rev* 2009;8:410-414.
5. Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness caused by photoreceptor degeneration as a remote effect of cancer. *Am J Ophthalmol* 1976;81:606-613.
6. Jacobson DM, Thirkill CE, Tipping SJ. A clinical triad to diagnose paraneoplastic retinopathy. *Ann Neurol* 1990;28:162-167.
7. Ferreyra HA, Jayasundera T, Khan NW, He S, Lu Y, Heckenlively JR. Management of autoimmune retinopathies with immunosuppression. *Arch Ophthalmol* 2009;127:390-397.
8. Forooghian F, Macdonald IM, Heckenlively JR, et al. The need for standardization of antiretinal antibody detection and measurement. *Am J Ophthalmol* 2008;146:489-495.
9. Jampol LM, Fishman GA. Immunosuppression for autoimmune retinopathy. *Arch Ophthalmol* 2009;127:573-575.
10. Heckenlively JR, Ferreyra HA, Jayasundera T, Janasundera T. Controversies of diagnosing autoimmune retinopathy. *Arch Ophthalmol* 2010;128:147-148; author reply 148-149.
11. Coker JG, Duker JS. Macular disease and optical coherence tomography. *Curr Opin Ophthalmol* 1996;7:33-38.
12. Drexler W, Sattmann H, Hermann B, et al. Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography. *Arch Ophthalmol* 2003;121:695-706.
13. Ko TH, Fujimoto JG, Schuman JS, et al. Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular pathology. *Ophthalmology* 2005;112:1922.e1921-1915.
14. Shildkrot Y, Sobrin L, Gragoudas ES. Cancer-associated retinopathy:

update on pathogenesis and therapy. *Semin Ophthalmol* 2011;26:321-328.

15. Pepple KL, Cusick M, Jaffe GJ, Mruthyunjaya P. SD-OCT and autofluorescence characteristics of autoimmune retinopathy. *Br J Ophthalmol* 2013;97:139-144.

16. Sakamori Y, Kim YH, Okuda C, et al. Two cases of cancer-associated retinopathy combined with small-cell lung cancer. *Jpn J Clin Oncol* 2011;41:669-673.

17. Marmor MF, Fulton AB, Holder GE, et al. ISCEV Standard for full-field clinical electroretinography (2008 update). *Doc Ophthalmol* 2009;118:69-77.

18. Ohta K, Kikuchi T, Yoshida N. Slowly progressive non-neoplastic autoimmune-like retinopathy. *Graefes Arch Clin Exp Ophthalmol* 2011;249:155-158.

19. Matsuo S, Ohguro H, Ohguro I, Nakazawa M. Clinicopathological Roles of Aberrantly Expressed Recoverin in Malignant Tumor Cells. *Ophthalmic Research* 2010;43.

20. Thirkill CE, Tait RC, Tyler NK, Roth AM, Keltner JL. The cancer-associated retinopathy antigen is a recoverin-like protein. *Invest Ophthalmol Vis Sci* 1992;33:2768-2772.

21. Adamus G, Guy J, Schmied JL, Arendt A, Hargrave PA. Role of anti-recoverin autoantibodies in cancer-associated retinopathy. *Invest Ophthalmol Vis Sci* 1993;34:2626-2633.

22. Matsuo S, Ohguro H, Ohguro I, Nakazawa M. Clinicopathological roles of aberrantly expressed recoverin in malignant tumor cells. *Ophthalmic Res* 2010;43:139-144.

23. Raghunath A, Adamus G, Bodurka DC, Liu J, Schiffman JS. Cancer-associated retinopathy in neuroendocrine carcinoma of the fallopian tube. *J Neuroophthalmol* 2010;30:252-254.

24. Keltner JL, Thirkill CE. Cancer-associated retinopathy vs recoverin-associated retinopathy. *Am J Ophthalmol* 1998;126:296-302.

25. Heckenlively JR, Fawzi AA, Oversier J, Jordan BL, Aptsiauri N. Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration. *Arch Ophthalmol* 2000;118:1525-1533.

26. Bazhin AV, Schadendorf D, Philippov PP, Eichmüller SB. Recoverin as a cancer-retina antigen. *Cancer Immunol Immunother* 2007;56:110-116.

27. Thirkill CE, Tait RC, Tyler NK, Roth AM, Keltner JL. Intraperitoneal cultivation of small-cell carcinoma induces expression of the retinal

cancer-associated retinopathy antigen. *Arch Ophthalmol* 1993;111:974-978.

28. Adamus G, Machnicki M, Seigel GM. Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. *Invest Ophthalmol Vis Sci* 1997;38:283-291.

29. Chen W, Elias RV, Cao W, Leriou V, McGinnis JF. Anti-recoverin antibodies cause the apoptotic death of mammalian photoreceptor cells in vitro. *J Neurosci Res* 1999;57:706-718.

30. Adamus G, Aptsiauri N, Guy J, Heckenlively J, Flannery J, Hargrave PA. The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. *Clin Immunol Immunopathol* 1996;78:120-129.

31. Ren G, Adamus G. Cellular targets of anti-alpha-enolase autoantibodies of patients with autoimmune retinopathy. *J Autoimmun* 2004;23:161-167.

32. Weleber RG, Watzke RC, Shults WT, et al. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. *Am J Ophthalmol* 2005;139:780-794.

33. Gilmour MA, Cardenas MR, Blaik MA, Bahr RJ, McGinnis JF. Evaluation of a comparative pathogenesis between cancer-associated retinopathy in humans and sudden acquired retinal degeneration syndrome in dogs via diagnostic imaging and western blot analysis. *Am J Vet Res* 2006;67:877-881.

34. Heckenlively JR, Jordan BL, Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. *Am J Ophthalmol* 1999;127:565-573.

35. Kikuchi T, Arai J, Shibuki H, Kawashima H, Yoshimura N. Tubby-like protein 1 as an autoantigen in cancer-associated retinopathy. *J Neuroimmunol* 2000;103:26-33.

36. Ohguro H, Ogawa K, Maeda T, Maeda A, Maruyama I. Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. *Invest Ophthalmol Vis Sci* 1999;40:3160-3167.

37. Ohguro H, Ogawa K, Nakagawa T. Recoverin and Hsc 70 are found as autoantigens in patients with cancer-associated retinopathy. *Invest Ophthalmol Vis Sci* 1999;40:82-89.

38. Potter MJ, Adamus G, Szabo SM, Lee R, Mohaseb K, Behn D. Autoantibodies to transducin in a patient with melanoma-associated retinopathy. *Am J Ophthalmol* 2002;134:128-130.

39. Eichen JG, Dalmau J, Demopoulos A, Wade D, Posner JB, Rosenfeld

- MR. The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. *J Neuroophthalmol* 2001;21:168-172.
40. Querques G, Thirkill CE, Hagege H, Soubrane G, Souied EH. Choroidal neovascularization associated with cancer-associated retinopathy. *Acta Ophthalmol* 2010;88:571-575.
 41. Dhingra A, Fina ME, Neinstein A, et al. Autoantibodies in melanoma-associated retinopathy target TRPM1 cation channels of retinal ON bipolar cells. *J Neurosci* 2011;31:3962-3967.
 42. Kondo M, Sanuki R, Ueno S, et al. Identification of autoantibodies against TRPM1 in patients with paraneoplastic retinopathy associated with ON bipolar cell dysfunction. *PLoS One* 2011;6:e19911.
 43. Thirkill CE, Roth AM, Keltner JL. Cancer-associated retinopathy. *Arch Ophthalmol* 1987;105:372-375.
 44. Peek R, Verbraak F, Coevoet HM, Kijlstra A. Müller cell-specific autoantibodies in a patient with progressive loss of vision. *Invest Ophthalmol Vis Sci* 1998;39:1976-1979.
 45. Lima LH, Greenberg JP, Greenstein VC, et al. Hyperautofluorescent ring in autoimmune retinopathy. *Retina* 2012;32:1385-1394.
 46. Shimazaki K, Jirawuthiworavong GV, Heckenlively JR, Gordon LK. Frequency of anti-retinal antibodies in normal human serum. *J Neuroophthalmol* 2008;28:5-11.
 47. Kim SJ, Toma HS, Thirkill CE, Dunn JP. Cancer-associated retinopathy with retinal periphlebitis in a patient with ovarian cancer. *Ocul Immunol Inflamm* 2010;18:107-109.
 48. Chin MS, Caruso RC, Detrick B, Hooks JJ. Autoantibodies to p75/LEDGF, a cell survival factor, found in patients with atypical retinal degeneration. *J Autoimmun* 2006;27:17-27.

Legends

Figure 1.

Electroretinogram of a patient with paraneoplastic retinopathy. Most patients showed reduced responses on both photopic and scotopic ERGs. Only case 6 showed normal scotopic responses. The numbers are matched to those presented in Table 1.

Figure 2.

Color fundus images (left row), fundus autofluorescence images (middle row) and spectral domain-optical coherence tomography (SD-OCT) images (right row) of 8 cases with paraneoplastic retinopathy.

The numbers are matched to those in the Table. All images are from the right eye. SD-OCT images are horizontal scan of case 2, 5, 6, and 8 and vertical scan of case 1, 3, 4, and 7. Autofluorescent images revealed the abnormal hyper- and/or hypo- autofluorescent lesions with an inter-individual variability in six cases. The SD-OCT images revealed retinal degeneration in all eyes.

Figure 3.

Western blot of mouse retina stained with patients' sera as the first antibodies. 10% SDS-PAGE is shown and the numbers are matched to those in the Table. Whether the bands were specific to retina or not was judged using lysates of other organs (graphic data not shown). The arrowhead shows retina-specific antibodies. The bands over 150 kDa were detected by 8% SDS-PAGE and they were not shown in this image.

Figure 4.

Comparison of spectral domain optical coherence tomography (SD-OCT) and immunohistochemistry (IHC) images of patients with paraneoplastic retinopathy. The numbers are matched to those in the Table. The top shows OCT images at higher magnification (1-8). Panels A-H are IHC images that show mouse retina stained with patient serum as the first antibody (green). Cell nuclei are visualized with DAPI (blue). S-100 protein was also used to label the Müller cell in case 1 (red). The control is presented on the bottom left panel. SD-OCT revealed abnormalities in external limiting membrane (ELM) or inner segment/outer segment junction (IS/OS) in all cases. IHC images showed that patients' sera contained antibodies that bind to various retinal proteins. White arrows indicate the site where anti-retinal antibodies in patient's sera reacted to retinal tissue. The scale bar represents 20 μ m. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; IS, inner segment of photoreceptor; OS, outer segment of photoreceptor.




Figure 1




Figure 2




Figure 3




Figure 4

Table. Clinical Characteristics and Treatment of Neoplasm and Pareneoplastic Retinopathy and Result of Western Blot Analysis of 8 Cases.

Case No., Age at Diagnosis, Sex	Chief Complaint	Initial BCVA		Visual Fields	Leakage in FA	ERG	Tumor		Treatment of Neoplasm	Treatment of Retinopathy	Serum Examination	Course
		R	L				Past History	New Discovery			WB(kD)*/ IHC	
Case1 85M	Defect of VF	1.5	1.0	B) Small islands scotoma	-	Subnormal	Bladder cancer and Liposarcoma in mediastinum	SCLC	Chemotherapy	Oral Prednisolone (Corticosteroid 25 mg/day)	36,39,43,64,74,217 / Müller cell	Died within 3 months
Case2 64F	Defect of VF and metamorphopsia	0.4	0.1	R) Ring scotoma L) Cental scotoma	+	Subnormal	no specific finding	SCLC	Chemotherapy and Radiation therapy	Oral Prednisolone (Corticosteroid 30 mg/day)	23,33,37,38,60,97,215 / OS of photoreceptor (s-cone)	VA stable for 2 years
Case3 57M	Decrease of VA and contraction of VF	0.15	0.01	R) Concentric contraction L) Central scotoma	+	Subnormal□	Thymoma	no specific finding	Surgery	Steroid therapy (pulse+oral), Plasmapheresis and IVlg	29,43,100 / O P L and IS of photoreceptor	Died within 1 year
Case4 81F	Decrease of VA	0.09	40 cm /HM	B) Central scotoma	+	Subnormal in cone NR in remainder	no specific finding	thymoma	Non-treatment	Ophthalmic solution (Betamethasone sodium phosphate)	17,21,34,41 / GCL and IS of photoreceptor	Drop out
Case5 78F	Decrease of VA and photopsia	0.15	0.08	R) Ring scotoma L) Islands scotoma	+	Subnormal	no specific finding	Pancreatic neuroendocrine neoplasm	Surgery	Steroid therapy(pulse+oral)□	46,48,60,63,98,189,222/ GCL,OPL and OS of photoreceptor	VA declined to 0.03 in both eyes in 9 months
Case6 59M	Decrease of VA and night blindness	0.8	1.2	R) Island scotoma L) N.P.	-	R) Subnormal L) Normal	Renal cancer	Brain metastasis	Renal :Operation Brain: Non-treatment	Non-treatment	34,71,94,102 / GCL, ,INL and OPL	VA stable for 2 years
Case7 61M	Decrease of VA	0.3	0.2	B) Ring scotoma and Concentric contraction	+	NR	Lymphoma (40years ago) and Renal cancer	no specific finding	Lymphoma: Radiation therapy Renal:Operation	Non-treatment	26, 46 ,75, 108 ,121/ GCL, INL and outside of RPE	VA declined to 0.07(right) and 0.05(left) in 10 months
Case8 68F	Decrease of VA and photopsia	0.3	0.03	B) Central and ring scotoma	-	Subnormal□	no specific finding	Colon cancer	Surgery	Non-treatment	25,30,90,174 / RPE	VA declined to hand motion in both eyes in 3 years

BCVA, best corrected visual acuity; FA, fluorescein angiography; WB, wester blot; IHC, immunohistochemistry; VF, visual field; SCLC, small cell lung cancer; IVlg, intravenous immunogloblin; OS, outer segment ; VA, visual acuity; HM, hand motion; NR, non-recordable; GCL, ganglion cell layer; IS, innner segment; OPL, outer plexiform layer; NP, not particular; INL, inner nuclear layer; RPE, retinal pigment epithelium. *Specific antibodies against retina or brain are marked in bold.